


Supplementary Figure: Scatterplot of CD4 count measurements within the first two years of HIV infection, with a Loess smoothing line and 95% confidence intervals, stratified by CAPRISA 004 1% tenofovir gel and placebo arms



**Supplementary Table: Comparison of the HIV VL of tenofovir and placebo arm seroconvertors according to VL assay used**

Measure	Tenofovir		Placebo		p-value
	n	Median (IQR)	n	Median (IQR)	
<b>Amplicor and Taqman assays (original analysis)</b>					
<i>VL at 12 months post infection (log copies/ml)</i>	30	4.24 (3.75 – 4.77)	45	3.70 (2.60 – 4.66)	<b>0.016</b>
<i>% with VL &lt;400 copies/ml (n)</i>	30	3.3% (1)	45	26.7% (12)	<b>0.011</b>
<b>Taqman version 2 assay (new VLs)</b>					
<i>VL at 12 months post infection (log copies/ml)</i>	30	4.40 (3.89 – 4.77)	45	3.97 (3.29 – 4.55)	<b>0.034</b>
<i>% with VL &lt;400 copies/ml (n)</i>	30	3.3% (1)	45	15.6% (7)	0.134